It was a pleasure collaborating with Cellazon to support Arda's therapeutic programs. Combining state-of-the-art data with sophisticated software and biological insight enables a new level of cellular precision in target discovery, advancing our mission to eliminate the cells that drive disease.
Accelerating Pathobiology-Driven Therapeutic Development with Arda Therapeutics Cellazon, a TechBio therapeutics company is redefining drug discovery through deep understanding of cell-to-cell interactions and pathway detection. We are excited to share the success of our collaboration with Arda Therapeutics, where Cellazon’s PathwayPersona™ platform played a role in accelerating therapeutic development for Idiopathic Pulmonary Fibrosis (IPF). PathwayPersona™ leveraged state-of-the-art spatial transcriptomics data, directly from patient biopsies, to uncover disease-causing cellular pathways and successfully validated pathogenic cell populations. Unlike traditional single-cell RNA-seq, which lack spatial context, this approach reveals how spatially distinct cell states contribute to IPF progression. Arda Therapeutics is proceeding to identify optimal surface proteins that could be used to eliminate these target pathogenic cell populations for therapeutic treatment of IPF. As we expand our collaborative network and resource base, we welcome partners interested in translating patient biology into real therapeutic breakthroughs.